Abeona acquires Phase III-ready ABO-801 drug assets from Ellodi in transaction worth up to $80 million plus royalties
Abeona Therapeutics has acquired the Phase III-ready eosinophilic oesophagitis candidate ABO-801 from Ellodi Pharmaceuticals in a share-based asset transaction with regulatory and commercial milestones, alongside a separate $30 million financing agreement.
Abeona announced on 9 November 2026 that it had completed the acquisition of Ellodi Pharmaceuticals' APT-1011 programme, renamed ABO-801, an orally disintegrating fluticasone propionate formulation being developed for eosinophilic oesophagitis, in exchange for $20 million of Abeona shares issued at closing and contingent payments tied to future regulatory and commercial achievements.
The transaction includes $30 million payable upon FDA approval, up to $30 million in sales milestones and low-to-mid-teen royalties, while Abeona's separately announced $30 million private placement provides financing rather than acquisition consideration and ABO-801's existing orphan and Fast Track designations do not constitute a new drug approval.
Field | Content |
Article Type | Deals |
Acquirer | Abeona Therapeutics |
Seller | Ellodi Pharmaceuticals |
Deal Type | Completed therapeutic asset acquisition |
Announcement Date | 9 November 2026 |
Transaction Status | Completed |
Acquired Programme | ABO-801 |
Former Programme Name | APT-1011 |
Active Ingredient | Fluticasone propionate |
Drug Formulation | Orally disintegrating formulation |
Therapeutic Area | Gastroenterology |
Target Indication | Eosinophilic oesophagitis |
Development Stage | Phase III-ready |
Total Specified Fixed and Contingent Consideration | Up to $80 million excluding royalties |
Consideration Paid at Closing | $20 million in Abeona shares |
Upfront Cash Consideration | None |
FDA Approval Milestone | $30 million contingent on FDA approval |
Sales Milestones | Up to $30 million |
Additional Royalty Consideration | Low-to-mid-teen royalties |
Royalty Base and Duration | Not specified in supplied summary |
Existing Orphan Drug Status | Previously designated |
Existing Fast Track Status | Previously designated |
New FDA Marketing Approval | No |
Separate Financing Transaction | $30 million private placement agreement |
Private Placement Purpose | Corporate financing |
Private Placement Classification | Not acquisition consideration |
Acquired Rights | ABO-801 development assets |
Next Development Step | Potential Phase III clinical development |
What Happened | Abeona completed an asset acquisition of the Phase III-ready ABO-801 programme from Ellodi Pharmaceuticals. |
Why It Matters | The transaction adds a late-stage gastrointestinal drug candidate to Abeona's development portfolio. |
Strategic Significance | Expands Abeona's pipeline through a transaction structured around equity consideration and future product milestones. |
Financial Clarification | The $80 million potential consideration comprises $20 million in shares and up to $60 million in milestones, excluding royalties; the separate $30 million financing is not part of the purchase price. |
Regulatory Clarification | Existing orphan and Fast Track designations do not indicate FDA marketing approval. |
Key Takeaway | Abeona acquired ABO-801 without upfront cash, with future payments dependent on approval and sales performance. |
What to Watch | Phase III trial plans, regulatory interactions, financing completion, FDA review and milestone achievement. |
Primary Source | Abeona Therapeutics SEC-filed announcement |
Primary Source URL | https://www.sec.gov/Archives/edgar/data/318306/000149315226050606/ex99-1.htm |
Relevant Date | 9 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Commentaires